CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 35 enrolled
Drug / intervention
Exparel +1 moredrug
Likely dose
Exparel 30 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03827291
NCT03827291Phase 4Completed
CompareCT.gov

Quantitative Observational Comparative Effectiveness of Quadratus Lumborum (QL) Block With Liposomal Bupivacaine (Exparel®) Versus Thoracic Epidural Analgesia in Patients Undergoing Laparoscopic Colectomy.

Duke University·interventional·Posted Feb 1, 2019·Updated Oct 16, 2025

In Brief

A Phase 4 clinical trial evaluating Exparel and Thoracic epidural analgesia for Laparotomy and Colectomy. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if using a different type of injection of local anesthestic (pain medicine) in between the muscle layers of the abdominal wall (called a quadratus lumborum block) will improve pain control and be easier to manage after surgery than the current standard of care epidural (spinal injection) pain relief for patients undergoing laparoscopy colectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLaparotomy, Colectomy
CountriesUnited States
CollaboratorsPacira Pharmaceuticals, Inc

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedFeb 1, 2019
Enrollment StartOct 31, 2019
Primary CompletionDec 2, 2022
Study CompletionDec 9, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.4 years ago

Interventions

Expareldrug

Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.

Thoracic epidural analgesiaother

Historical cohort that received thoracic epidural analgesia